Jetstream invested in Rejuvenation Technologies because it combines differentiated biology, founder-developed technology, and the potential for one therapeutic platform to address multiple serious diseases. Its transient mRNA approach is designed to extend critically short telomeres without permanently activating telomerase, while targeted lipid nanoparticles provide tissue-level delivery. With programs spanning lung, liver, and hematologic disease, a substantial patent portfolio, and founders deeply connected to the underlying science, Rejuvenation represents the kind of highly technical platform opportunity Jetstream seeks to identify early.